Global Brain has invested in Alpha Fusion Inc. (Alpha Fusion), a company developing Astatine based innovative alpha therapies, through its JGC MIRAI Innovation Fund L.P. (JGC MIRAI Innovation Fund). Alpha Fusion is a drug discovery company that unleashes the potential of Astatine (At-211) based alpha radiotherapy drugs to contribute to cancer treatment globally. In the field of targeted alpha particle emitters which recently has been getting attention worldwide, Alpha Fusion, by collaborating with research institutions such as Osaka University and major manufacturers of cyclotron in Japan, has been expanding the possibilities of Astatine based drug discovery and its world-class innovative pipelines and platform. Targeted alpha radiotherapy drugs using Astatine is expected to be a novel cancer treatment with unprecedented high efficacy and safety as it treats cancers with unmet medical needs and metastasis like a micro-level precision surgery. Global Brain has decided to invest in Alpha Fusion for of its uniqueness of Astatine, high unmet medical needs in cancer area, and management with expertise in this field. Global Brain will contribute to the business growth of Alpha Fusion in collaboration with JGC JAPAN CORPORATION.

About Alpha Fusion

Location: Kita-ku, Osaka, Japan
CEO: Sunao Fujioka
Founded: Apr 2021
URL: https://alpha-fusion.com/

About JGC MIRAI Innovation Fund

Name: JGC MIRAI Innovation Fund L.P.
General Partner: Global Brain Corporation
Fund Size: JPY 5 billion
Fund Term: 10 years

About Global Brain

Location: Tokyo, Japan
Representative: Yasuhiko Yurimoto
Founded: January 1998
URL: https://globalbrains.com/

Global Brain has invested in Alpha Fusion Inc., a drug discovery startup developing next generation alpha radiotherapy drugs with Astatine for multiple cancers